The trial investigates the combination of Camrelizumab, a PD-1 inhibitor, and Famitinib, a VEGFR inhibitor, for adjuvant treatment in high-risk stage II-IIIA non-small cell lung cancer (NSCLC) patients without driver gene mutations. This combination therapy aims to leverage the immunomodulatory effects of Camrelizumab alongside the anti-angiogenic properties of Famitinib, potentially enhancing treatment outcomes. The NSCLC market is competitive, with several established therapies; however, the focus on high-risk patients without driver mutations may provide a niche opportunity. Successful outcomes could position the combination as a new standard of care, impacting market dynamics significantly. Diligence should consider existing therapies, market access strategies, and potential partnerships for commercialization.